Medical Management of Primary Hyperparathyroidism

Journal of Clinical Densitometry

Volumn 16, Issue 1, 2013, Pages 60-63

  Khan, Aliya A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bisphosphonates; Cinacalcet; Estrogen; Medical management; Primary hyperparathyroidism; Raloxifene

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; DENOSUMAB; ESTROGEN; ODANACATIB; PARATHYROID HORMONE;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE STRENGTH; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; KIDNEY CALCIFICATION; KIDNEY DYSFUNCTION; NEPHROLITHIASIS; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RISK FACTOR; VITAMIN SUPPLEMENTATION;

CALCIMIMETIC AGENTS; CALCIUM; DIPHOSPHONATES; HOMEOSTASIS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; NAPHTHALENES; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

EID: 84873204704     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2012.11.010     Document Type: Article

References (21)

1. Pallan S., Rahman M.O., Khan A.A. Hyperparathyroidism: diagnosis and management-a clinical review. BMJ 2012, 344:e1013. 10.1136/bmj.e1013.
2. Khan A., Grey A., Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceeding of the third international workshop. J Clin Endocrinol Metab 2009, 94:373-381.
3. Udelsman R., Pasieka J.L., Sturgeon C., et al. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94:366-372.
4. Eastell R., Arnold A., Brandi M.L., et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94:340-350.
5. Silverberg S.J., Lewiecki E.M., Mosekilde L., et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94:351-365.
6. Beyer T.D., Chen E., Nilubol N., et al. Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin D insufficiency. J Surg Res 2007, 143:145-150.
7. Rao D.S., Agarwal G., Talpos G.B., et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002, 17(Suppl 2):N75-N80.
8. Grey A., Lucas J., Horne A., et al. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005, 90:2122-2126.
9. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94:335-339. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism.
10. Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19:558-567.
11. Schmidli R.S., Wilson I., Espiner E.A., et al. Aminopropylidine diphosphonate (ADP) in mild primary hyperparathyroidism: effects on clinical status. Clin Endocrinol (Oxf) 1990, 32:293-300.
12. Reasner C.A., Stone M.D., Hosking D.J., et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993, 77:1067-1071.
13. Rossini M., Gatti D., Isaia G., et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001, 16:113-119.
14. Chow C.C., Chan W.B., Li J.K., et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 85:581-587.
15. Khan A.A., Bilezikian J.P., Kung A.W., et al. Alendronate in primary hyperparathyroidism: a double blind, randomized, placebo controlled trial. J Clin Endocrinol Metab 2004, 89:3319-3325.
16. Grey A.B., Stapleton J.P., Evans M.C., et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal woman with mild primary hyperparathyroidism: a randomized, controlled trial. Ann Intern Med 1996, 125:360-368.
17. Rubin M.R., Lee K.H., McMahon D.J., Silverberg S.J. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88:1174-1178.
18. Zanchetta J.R., Bogado C.E. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 2001, 16:189-190.
19. Peacock M., Bilezikian J.P., Klassen P.S., et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90:135-141.
20. Peacock M., Bolognese M.A., Brofsky M., et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009, 94:2766-2772.
21. Silverberg S.J., Rubin M.R., Faiman C., et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007, 92:3803-3808.